Kazia Therapeutics Ltd NVGNF:Grey Market

RT Quote | Exchange | USD
Last | 09/02/19 EST
0.20UNCH (UNCH)
52 week range
0.20 - 0.20

...

Loading . . .

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.20
  • 52 Week High0.20
  • 52 Week High Date09/03/19
  • 52 Week Low0.20
  • 52 Week Low Date09/03/19
  • Market Cap124.42M
  • Shares Out126.17M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.10
  • P/E (TTM)-1.94
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Kazia Therapeutics Ltd News

There is no recent news for this security.

Latest NVGNF News From Our Partners

QUOTE FINDER

Profile

MORE
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507)...
Iain Ross
Non-Executive Chairman
James Garner
Chief Executive Officer
Address
L 5 20 George St, Hornsby
Sydney, NSW
2077
Australia